XML 80 R17.htm IDEA: XBRL DOCUMENT
v3.25.1

Share capital | 12 Months Ended
--- | ---
Dec. 31, 2024
Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract] |
Share capital | Note 10. Share capital 10.1. Capital issued Accounting policies Ordinary shares are classified in shareholders’ equity. The cost of equity transactions that are directly attributable to the issue of new shares or options is recognized in shareholders’ equity as a deduction from the proceeds of the issue. Capital management The Company’s objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders, and maintain an optimal capital structure to reduce the cost of capital while maintaining the necessary flexibility. Detail of share capital transactions
(in thousands or number of shares) | Nature of transaction | Share Capital | Premiums related to share capital | Number of shares
December 31, 2022 |  | 1,046 |  | 255,760 |  | 34,875,872 |
April 20, 2023 | Capital increase (AGA 2021) | 11 |  | — |  | 354,510 |
June 27, 2023 | Free Shares attributions (AGA 2023) | — |  | (26) |  | — |
September 11, 2023 | Issuance of new shares - Capital increase (Tranche 1 Janssen) | 29 |  | 4,642 |  | 959,637 |
November 7, 2023 | Issuance of new shares - capital increase (ordinary shares) | 75 |  | 12,561 |  | 2,492,223 |
November 7, 2023 | Issuance of new shares - capital increase (ADS) | 114 |  | 19,086 |  | 3,786,907 |
November 7, 2023 | Capital increase transaction costs (ordinary shares) | — |  | (758) |  | — |
November 7, 2023 | Capital increase transactions costs (ADS) | — |  | (1,140) |  | — |
November 10, 2023 | Issuance of new shares - Capital increase (Tranche 2 - step 1 Janssen) | 113 |  | 18,965 |  | 3,762,923 |
December, 13, 2023 | Issuance of new shares - Capital increase (Tranche 2 - step 2 Janssen) | 27 |  | 4,542 |  | 901,256 |
December, 29, 2023 | Capital increase transactions costs | — |  | (79) |  | — |
December, 29, 2023 | Capital increase transactions costs | — |  | (813) |  | — |
December, 31, 2023 | Prior period adjustments | — |  | 1 |  | — |
December 31, 2023 |  | 1,414 |  | 312,742 |  | 47,133,328 |
June 22, 2024 | Capital increase (AGA 2022) | 9 |  | — |  | 293,523 |
December 31, 2024 | Prior period adjustments |  | 1 |  |
December 31, 2024 |  | 1,423 |  | 312,743 |  | 47,426,851 |
As of December 31, 2024, the share capital was €1,422,805.53 divided into 47,426,851 fully paid in ordinary shares each with a par value of €0.03, as compared with the 2023 share capital of €1,413,999.85 divided into 47,133,328 fully paid in ordinary shares, each with a par value of €0.03. On June 22, 2024, the share capital of the Company was increased by a nominal amount of €8,805.69, through the issuance of 293,523 new ordinary shares with a nominal value of €0.03 each, increasing the Company’s share capital from €1,413,999.85 to €1,422,805.53, as a result of the definitive acquisition of 293,523 AGA 2022. Such acquisition was acknowledged by the Executive Board on June 19, 2024. On April 20, 2023, the share capital of the Company was increased by a nominal amount of €10,635.30, through the issuance of 354,510 new ordinary shares with a nominal value of €0.03 each, increasing the Company’s share capital from €1,046,276.16 to €1,056,911.46, as a result of the definitive acquisition of 354,510 AGA 2021. Such acquisition was acknowledged by the Executive Board on March 28, 2023 and on June 6, 2023. In 2023, the share capital of the Company was also successively increased following the Securities Purchase Agreement with Johnson & Johnson Innovations—JJDC: –On September 11, 2023, the share capital of the Company was increased by a nominal amount of €28,789.11, due to the issuance to JJDC of 959,637 new ordinary shares with a nominal value of €0.03 each, and the Company also recorded an increase in reserves of €4.2 million; –On November 7, 2023, following the completion of the settlement and delivery of the Global Offering, the share capital of the Company was increased by a nominal amount of €188,373.90, through the issuance of 6,279,130 new ordinary shares with a nominal value of €0.03 each; –On November 10, 2023, following the completion of the settlement and delivery of the Strategic Offering, the share capital of the Company was increased by a nominal amount of €112,887.69, through the issuance of 3,762,923 new ordinary shares with a nominal value of €0.03 each; –On December 13, 2023, the share capital of the Company was increased by a nominal amount of €27,037.68, through the issuance of 901,256 new ordinary shares with a nominal value of €0.03 each. Distribution of dividends The Company did not distribute any dividends for any of the periods presented, does not have any present plan to pay any cash dividends on its equity securities in the foreseeable future and currently intends to retain all available funds and any future earnings to operate clinical trials and expand our business. Allocation of prior period (loss) The negative net result for the year 2023 of €39.7 million has been fully allocated to reserves. 10.2. Treasury shares On December 20, 2022 the liquidity contract with Gilbert Dupont was terminated, resulting in the Company receiving 22,118 shares that are still reported as treasury shares as of December 31, 2024. 10.3. Founders’ warrants, warrants, stock options and free shares Accounting policies Accounting policies for share-based payments are described in Note 18. Detail of change in founders’ warrants, warrants, stock options and free shares The Company has granted stock options (OSA), founders’ warrants (BSPCE), warrants (BSA), and free shares (AGA) to corporate officers, employees, members of the Executive and Supervisory Board and consultants of the Group. In certain cases, exercise of the stock options, founders’ warrants and warrants is subject to performance conditions. The Company has no legal or contractual obligation to pay the options in cash. The following tables summarize activity in these plans during the years ended December 31, 2024 and 2023. The impact of share-based payments on income is detailed in Note 18. Founders’ warrants (BSPCE)
Type |  | Grant date |  | Exercise price (in euros) |  | Outstanding at January 1, 2024 |  | Issued |  | Exercised |  | Forfeited |  | Outstanding at December 31, 2024 |  | Number of shares issuable
BSPCE 08-2013 |  | August 28, 2013 |  | 5.92 |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | —
BSPCE 09-2014 |  | September 16, 2014 |  | 18.68 |  | 85,750 |  |  | — |  |  | — |  |  | (85,750) |  |  | — |  |  | —
BSPCE 2015-1 |  | February 10, 2015 |  | 18.57 |  | 68,100 |  |  | — |  |  | — |  |  | (350) |  |  | 67,750 |  |  | 67,750
BSPCE 2015-3 |  | June 10, 2015 |  | 20.28 |  | 28,400 |  |  | — |  |  | — |  |  | (1,050) |  |  | 27,350 |  |  | 27,350
BSPCE 2016 |  | February 2, 2016 |  | 14.46 |  | 197,017 |  |  | — |  |  | — |  |  | (2,100) |  |  | 194,917 |  |  | 194,917
BSPCE 2017 |  | January 7, 2017 |  | 15.93 |  | 178,100 |  |  | — |  |  | — |  |  | (1,050) |  |  | 177,050 |  |  | 177,050
Total |  |  |  |  |  | 557,367 |  |  | — |  |  | — |  |  | (90,300) |  |  | 467,067 |  |  | 467,067
Type |  | Grant date |  | Exercise price (in euros) |  | Outstanding at January 1, 2023 |  | Issued |  | Exercised |  | Forfeited |  | Outstanding at December 31, 2023 |  | Number of shares issuable
BSPCE 08-2013 |  | August 28, 2013 |  | 5.92 |  | 50,000 |  |  | — |  |  | — |  |  | (50,000) |  |  | — |  |  | 0
BSPCE 09-2014 |  | September 16, 2014 |  | 18.68 |  | 86,150 |  |  | — |  |  | — |  |  | (400) |  |  | 85,750 |  |  | 85,750
BSPCE 2015-1 |  | February 10, 2015 |  | 18.57 |  | 68,450 |  |  | — |  |  | — |  |  | (350) |  |  | 68,100 |  |  | 68,100
BSPCE 2015-3 |  | June 10, 2015 |  | 20.28 |  | 30,350 |  |  | — |  |  | — |  |  | (1,950) |  |  | 28,400 |  |  | 28,400
BSPCE 2016 |  | February 2, 2016 |  | 14.46 |  | 200,626 |  |  | — |  |  | — |  |  | (3,609) |  |  | 197,017 |  |  | 197,017
BSPCE 2017 |  | January 7, 2017 |  | 15.93 |  | 179,150 |  |  | — |  |  | — |  |  | (1,050) |  |  | 178,100 |  |  | 178,100
Total |  |  |  |  |  | 614,726 |  |  | — |  |  | — |  |  | (57,359) |  |  | 557,367 |  |  | 557,367
By way of exception, the Executive Board decided to lift, for two former employees and for two former members of the Executive Board, the continued service condition, and, where applicable for a former Executive Board member, the performance conditions to which the exercise of certain BSPCEs was subject, notwithstanding the termination of their employment agreement and/or corporate office. The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was updated as of December 31, 2024. The threshold of 500 patients enrolled in all our clinical studies was exceeded in December 31, 2023. As a consequence, all outstanding 2016 BSPCE, BSA and OSA may be exercised. The impact of share-based payments on income is detailed in Note 18. Warrant Plans (BSA)
Type |  | Grant date |  | Exercise price (in euros) |  | Outstanding at January 1, 2024 |  | Issued |  | Exercised |  | Forfeited |  | Outstanding at December 31, 2024 |  | Number of shares issuable*
BSA 2013 |  | April 10, 2013 |  | 6.37 |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
BSA 2014 |  | September 16, 2014 |  | 17.67 |  | 10,000 |  |  | — |  |  | — |  |  | (10,000) |  |  | — |  |  | — |
BSA 2015-1 |  | February 10, 2015 |  | 17.67 |  | 21,000 |  |  | — |  |  | — |  |  | — |  |  | 21,000 |  |  | — |
BSA 2015-2(a) |  | June 25, 2015 |  | 19.54 |  | 64,000 |  |  | — |  |  | — |  |  | — |  |  | 64,000 |  |  | — |
BSA 2018-1 |  | March 6, 2018 |  | 13.55 |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
BSA 2018-2 |  | July 27, 2018 |  | 16.10 |  | 5,820 |  |  | — |  |  | — |  |  | — |  |  | 5,820 |  |  | — |
BSA 2019-1 |  | March 29, 2019 |  | 11.66 |  | 18,000 |  |  | — |  |  | — |  |  | — |  |  | 18,000 |  |  | — |
BSA 2020 |  | March 17, 2020 |  | 6.59 |  | 18,000 |  |  | — |  |  | — |  |  | — |  |  | 18,000 |  |  | — |
BSA 2021 (a) |  | April 21, 2021 |  | 13.47 |  | 14,431 |  |  | — |  |  | — |  |  | — |  |  | 14,431 |  |  | 14,431 |
Total |  |  |  |  |  | 151,251 |  |  | — |  |  | — |  |  | (10,000) |  |  | 141,251 |  |  | 14,431 |
Type |  | Grant date |  | Exercise price (in euros) |  | Outstanding at January 1, 2023 |  | Issued |  | Exercised |  | Forfeited |  | Outstanding at December 31, 2023 |  | Number of shares issuable*
BSA 2013 |  | April 10, 2013 |  | 6.37 |  | 6,000 |  |  | — |  |  | — |  |  | (6,000) |  |  | — |  |  | — |
BSA 2014 |  | September 16, 2014 |  | 17.67 |  | 10,000 |  |  | — |  |  | — |  |  | — |  |  | 10,000 |  |  | — |
BSA 2015-1 |  | February 10, 2015 |  | 17.67 |  | 21,000 |  |  | — |  |  | — |  |  | — |  |  | 21,000 |  |  | — |
BSA 2015-2(a) |  | June 25, 2015 |  | 19.54 |  | 64,000 |  |  | — |  |  | — |  |  | — |  |  | 64,000 |  |  | — |
BSA 2018-1 |  | March 6, 2018 |  | 13.55 |  | 28,000 |  |  | — |  |  | — |  |  | (28,000) |  |  | — |  |  | — |
BSA 2018-2 |  | July 27, 2018 |  | 16.10 |  | 5,820 |  |  | — |  |  | — |  |  | — |  |  | 5,820 |  |  | — |
BSA 2019-1 |  | March 29, 2019 |  | 11.66 |  | 18,000 |  |  | — |  |  | — |  |  | — |  |  | 18,000 |  |  | — |
BSA 2020 |  | March 17, 2020 |  | 6.59 |  | 18,000 |  |  | — |  |  | — |  |  | — |  |  | 18,000 |  |  | — |
BSA 2021 (a) |  | April 21, 2021 |  | 13.47 |  | 14,431 |  |  | — |  |  | — |  |  | — |  |  | 14,431 |  |  | 14,431 |
Total |  |  |  |  |  | 185,251 |  |  | — |  |  | — |  |  | (34,000) |  |  | 151,251 |  |  | 14,431 |
*Number of shares issuable subject to performance conditions During the year ended December 31, 2024, no new warrants were issued. At a meeting on September 16, 2014, the Executive Board, acting pursuant to the delegation, granted 14,000 warrants to members and observers of the Supervisory Board, each warrant giving its holder the right to subscribe to one ordinary share, each with a par value of €0.03 and at a price of €17.67 (share premium included). The subscription period is open from the date of the Executive Board until September 16, 2024, inclusive. As of December 31, 2024, the remaining 10,000 warrants have not been exercised by their beneficiaries and have all been cancelled. Stock Option Plans (OSA)
Type |  | Grant date |  | Exercise price (in euros) |  | Outstanding at January 1, 2024 |  | Issued |  | Exercised |  | Forfeited |  | Outstanding at December 31, 2024 |  | Number of shares issuable
OSA 2016-1 |  | February 2, 2016 |  | 13.05 |  | 400 |  |  | — |  |  | — |  |  | — |  |  | 400 |  |  | 400 |
OSA 2016-2 |  | November 3, 2016 |  | 14.26 |  | 4,000 |  |  | — |  |  | — |  |  | — |  |  | 4,000 |  |  | 4,000 |
OSA 2017 |  | January 7, 2017 |  | 14.97 |  | 500 |  |  | — |  |  | — |  |  | — |  |  | 500 |  |  | 500 |
OSA 2018 |  | March 6, 2018 |  | 12.87 |  | 52,000 |  |  | — |  |  | — |  |  | (2,000) |  |  | 50,000 |  |  | 50,000 |
OSA 2019-1 |  | March 29, 2019 |  | 11.08 |  | 25,750 |  |  | — |  |  | — |  |  | (1,000) |  |  | 24,750 |  |  | 24,750 |
OSA LLY 2019 |  | October 24, 2019 |  | 6.41 |  | 500,000 |  |  | — |  |  | — |  |  | — |  |  | 500,000 |  |  | — |
OSA 2020 |  | March 11, 2020 |  | 6.25 |  | 377,775 |  |  | — |  |  | — |  |  | (9,068) |  |  | 368,707 |  |  | 368,707 |
OSA 2021-04 |  | April 20, 2021 |  | 13.74 |  | 396,200 |  |  | — |  |  | — |  |  | (12,068) |  |  | 384,132 |  |  | 38,532 |
OSA 2021-06 |  | June 21, 2021 |  | 12.99 |  | 120,000 |  |  | — |  |  | — |  |  | — |  |  | 120,000 |  |  | 60,000 |
OSA 2022-06 |  | June 22, 2022 |  | 4.16 |  | 540,690 |  |  | — |  |  | — |  |  | (21,277) |  |  | 519,413 |  |  | 286,750 |
OSA 2023-01 |  | July 20, 2023 |  | 5.00 |  | 318,860 |  |  | — |  |  | — |  |  | — |  |  | 318,860 |  |  | 106,288 |
OSA 2024-01 |  | May 23, 2024 |  | 5.81 |  | — |  |  | 1,224,780 |  |  | — |  |  | (3,240) |  |  | 1,221,540 |  |  | — |
Total |  |  |  |  |  | 2,336,175 |  |  | 1,224,780 |  |  | — |  |  | (48,653) |  |  | 3,512,302 |  |  | 939,927 |
Type |  | Grant date |  | Exercise price (in euros) |  | Outstanding at January 1, 2023 |  | Issued |  | Exercised |  | Forfeited |  | Outstanding at December 31, 2023 |  | Number of shares issuable
OSA 2016-1 |  | February 2, 2016 |  | 13.05 |  | 400 |  |  | — |  |  | — |  |  | — |  |  | 400 |  |  | 400 |
OSA 2016-2 |  | November 3, 2016 |  | 14.26 |  | 4,000 |  |  | — |  |  | — |  |  | — |  |  | 4,000 |  |  | 4,000 |
OSA 2017 |  | January 7, 2017 |  | 14.97 |  | 500 |  |  | — |  |  | — |  |  | — |  |  | 500 |  |  | 500 |
OSA 2018 |  | March 6, 2018 |  | 12.87 |  | 52,000 |  |  | — |  |  | — |  |  | — |  |  | 52,000 |  |  | 52,000 |
OSA 2019-1 |  | March 29, 2019 |  | 11.08 |  | 25,750 |  |  | — |  |  | — |  |  | — |  |  | 25,750 |  |  | 25,750 |
OSA LLY 2019 |  | October 24, 2019 |  | 6.41 |  | 500,000 |  |  | — |  |  | — |  |  | — |  |  | 500,000 |  |  | — |
OSA 2020 |  | March 11, 2020 |  | 6.25 |  | 381,173 |  |  | — |  |  | — |  |  | (3,398) |  |  | 377,775 |  |  | 377,775 |
OSA 2021-04 |  | April 20, 2021 |  | 13.74 |  | 421,200 |  |  | — |  |  | — |  |  | (25,000) |  |  | 396,200 |  |  | 30,134 |
OSA 2021-06 |  | June 21, 2021 |  | 12.99 |  | 120,000 |  |  | — |  |  | — |  |  | — |  |  | 120,000 |  |  | 40,000 |
OSA 2022-06 |  | June 22, 2022 |  | 4.16 |  | 554,500 |  |  | — |  |  | — |  |  | (13,810) |  |  | 540,690 |  |  | 140,500 |
OSA 2023-01 |  | July 20, 2023 |  | 5.00 |  | — |  |  | 338,860 |  |  | — |  |  | (20,000) |  |  | 318,860 |  |  | — |
Total |  |  |  |  |  | 2,059,523 |  |  | 338,860 |  |  | — |  |  | (62,208) |  |  | 2,336,175 |  |  | 671,059 |
At a meeting on May 23, 2024, the Executive Board, acting pursuant to delegations granted by the Company’s shareholders’ meeting held on July 20, 2023, granted to certain employees of the Group and members of the Executive Board 1,224,780 stock options, each giving its holder the right to subscribe to one ordinary share, each with a par value of €0.03 and at a price of €5.81 (share premium included). Such stock options are governed by the 2023 stock option plan, adopted by the Executive Board on July 20, 2023 and approved by the Company’s annual shareholders’ meeting held on June 27, 2023 (the “2023 Stock Option Plan”). The ordinary stock options are exercisable as follows: ▪up to one-third of the ordinary stock options as from May 23, 2025; ▪ an additional one-third of the ordinary stock options as from May 23, 2026; and ▪ the balance, i.e., one-third of the ordinary stock options as from May 23, 2027. subject to, for each increment, a continued service condition, and in any case, no later than 10 years after the date of grant. Stock options which have not been exercised by the end of the 10 year period will be forfeited by law. Free share plans (AGA)
Type |  | Grant date |  |  |  | Outstanding at January 1, 2024 |  | Issued |  | Definitively vested |  | Forfeited |  | Outstanding at December 31, 2024 |  | Number of shares exercisable
AGA 2021 |  | April 20, 2021 |  |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
AGA 2022 |  | June 22, 2022 |  |  |  | 293,776 |  |  | — |  |  | (293,523) |  |  | (253) |  |  | — |  |  | — |
AGA 2023 - P1 |  | June 27, 2023 |  |  |  | 400,960 |  |  | — |  |  | — |  |  | (8,500) |  |  | 392,460 |  |  | 392,460 |
AGA 2023 - P2 |  | June 27, 2023 |  |  |  | 432,560 |  |  | — |  |  | — |  |  | (9,100) |  |  | 423,460 |  |  | 423,460 |
Total |  |  |  |  |  | 1,127,296 |  |  | — |  |  | (293,523) |  |  | (17,853) |  |  | 815,920 |  |  | 815,920 |
Type |  | Grant date |  |  |  | Outstanding at January 1, 2023 |  | Issued |  | Definitively vested |  | Forfeited |  | Outstanding at December 31, 2023 |  | Number of shares exercisable
AGA 2021 |  | April 20, 2021 |  |  |  | 354,711 |  |  | — |  |  | (354,510) |  |  | (201) |  |  | — |  |  | — |
AGA 2022 |  | June 22, 2022 |  |  |  | 299,035 |  |  | — |  |  | — |  |  | (5,259) |  |  | 293,776 |  |  | 293,776 |
AGA 2023 - P1 |  | June 27, 2023 |  |  |  | — |  |  | 427,110 |  |  | — |  |  | (26,150) |  |  | 400,960 |  |  | 400,960 |
AGA 2023 - P2 |  | June 27, 2023 |  |  |  | — |  |  | 439,210 |  |  | — |  |  | (6,650) |  |  | 432,560 |  |  | 432,560 |
Total |  |  |  |  |  | 653,746 |  |  | 866,320 |  |  | (354,510) |  |  | (38,260) |  |  | 1,127,296 |  |  | 1,127,296 |
No free shares were granted in 2024. At a meeting on June 27, 2023, the Executive Board, acting pursuant to the authorization granted by Company’s shareholders’ meeting on June 23, 2022, granted 427,110 free shares (AGA 2023 P1), each with a par value of €0.03 to employees of the Group and members of the Executive Board. Such free shares will be subject to a one-year holding period starting at the end of the two-year acquisition period, i.e. starting on June 27, 2025. Such free shares are governed by the 2023 free share plan adopted by the Executive Board on June 27, 2023. At a meeting on June 27, 2023, the Executive Board, acting pursuant to the authorization granted by Company’s shareholders’ meeting on June 23, 2022, granted 439,210 free shares (AGA 2023 P2), each with a par value of €0.03 to certain employees of the Group and members of the Executive Board. Such free shares will be subject to a one-year holding period starting at the end of the two-year acquisition period, i.e. starting on June 27, 2025. Such free shares are governed by the 2023 free share plan adopted by the Executive Board on June 27, 2023. Furthermore, the definitive acquisition of the AGA 2023-P1 and the AGA 2023-P2 were conditioned upon the achievement of performance conditions applicable within the acquisition period. The satisfaction of these performance condition was acknowledged by the Executive Board, with the approval of the Supervisory Board on February 09, 2024. Free share vesting conditions The AGA 2023 are subject to a two-year vesting period and a one-year holding period. The free shares granted by the Company are definitively acquired at the end of the acquisition period as set by the Executive Board. At the end of such period, the beneficiary is the owner of the shares. However, during the holding period (as set by the Executive Board), if any, the shares may not be sold, transferred or pledged. Unless otherwise decided by the supervisory and executive boards of the Company, the AGA 2023 are subject to continued service during the vesting period (i.e. until June 27, 2025), it being specified that, failing such continued service, the beneficiary definitively and irrevocably loses his or her right to acquire the relevant AGA 2023. Unless otherwise decided by the supervisory and executive boards of the Company, in the event of disability or death of a beneficiary before the end of the acquisition period, the relevant free shares shall be definitely acquired at, respectively, the date of disability or the date of the request of allocation made by his or her beneficiary in the framework of the inheritance, provided that such request is made within six months from the date of death. At a meeting on June 22, 2024, the Executive Board acknowledged the definitive acquisition of 293,523 free shares granted on June 22, 2022 following a two-year acquisition period, thus acknowledging the related share capital increase of €8,805.69. In accordance with the AGA Plans, the executive board decided to lift, for one of our employees, the continued service condition to which the definitive acquisition of their AGA 2023-P1, and for two of our employees, the continued service condition to which the definitive acquisition of their AGA 2023-P2, as applicable, is subject, notwithstanding the termination of their employment agreement. The impact of share-based payments on income is disclosed in Note 18. As of December 31, 2024, the assumptions related to the estimated vesting of the founders’ warrants, the warrants and performance stock-options have been updated (see Note 18 - Share-based payments). 10.4. Warrants (BSA) Equity Line KEPLER CHEUVREUX The existing equity line expired on September 15, 2024 is subsequently no longer effective as at December 31, 2024. No warrants has been exercised as of September 15, 2024.

X
- Definition The entire disclosure for share capital, reserves and other equity interest. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 79 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract] + References No definition available. + Details
Name: | nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract
Namespace Prefix: | nbx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration